Axsome Therapeutics - AXSM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $105.57
  • Forecasted Upside: 42.41%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.01 (0.01%)

This chart shows the closing price for AXSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

Analyst Price Target is $105.57
▲ +42.41% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $105.57, with a high forecast of $200.00 and a low forecast of $52.00. The average price target represents a 42.41% upside from the last price of $74.13.

This chart shows the closing price for AXSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Axsome Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2023MizuhoBoost Target$84.00 ➝ $95.00Low
5/9/2023GuggenheimBoost Target$90.00 ➝ $100.00Low
5/9/2023Morgan StanleyBoost Target$83.00 ➝ $87.00Low
4/17/2023HC WainwrightReiterated RatingBuy$200.00Low
4/12/2023Morgan StanleyLower TargetEqual Weight$85.00 ➝ $83.00Low
3/20/2023HC WainwrightLower Target$210.00 ➝ $200.00Low
3/13/2023MizuhoReiterated RatingBuy$84.00Low
3/6/2023HC WainwrightReiterated RatingBuy$210.00Low
3/1/2023MizuhoLower TargetBuy$86.00 ➝ $84.00Low
2/28/2023GuggenheimLower TargetBuy$105.00 ➝ $90.00Low
2/28/2023Morgan StanleyLower TargetEqual Weight$86.00 ➝ $85.00Low
2/14/2023Bank of AmericaReiterated RatingUnderperform$52.00Low
2/14/2023HC WainwrightReiterated RatingBuy$210.00N/A
1/30/2023MizuhoBoost TargetBuy$80.00 ➝ $86.00Low
1/5/2023Piper SandlerInitiated CoverageNeutral$75.00Low
12/23/2022BTIG ResearchBoost TargetBuy$62.00 ➝ $98.00Low
11/29/2022Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $86.00Low
11/29/2022SVB LeerinkBoost TargetOutperform$65.00 ➝ $85.00Low
11/28/2022MizuhoReiterated RatingBuy$80.00Low
11/15/2022MizuhoBoost Target$80.00N/A
11/11/2022GuggenheimBoost TargetBuy$72.00 ➝ $80.00Low
11/9/2022MizuhoBoost TargetBuy$76.00 ➝ $80.00Low
11/8/2022Morgan StanleyLower TargetEqual Weight$74.00 ➝ $73.00Low
11/8/2022Cantor FitzgeraldBoost Target$88.00 ➝ $96.00Low
11/1/2022Loop CapitalInitiated CoverageBuy$95.00Low
10/14/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $74.00Low
10/14/2022GuggenheimBoost TargetBuy$64.00 ➝ $72.00Low
10/5/2022CowenLower Target$125.00Low
10/4/2022HC WainwrightReiterated RatingBuy$210.00Low
9/30/2022Morgan StanleyLower TargetEqual Weight$75.00 ➝ $71.00Low
9/30/2022Jefferies Financial GroupLower TargetBuy$92.00 ➝ $90.00Low
9/7/2022MizuhoBoost TargetBuy$49.00 ➝ $76.00Low
8/30/2022Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $75.00Low
8/23/2022HC WainwrightBoost TargetBuy$180.00 ➝ $210.00Low
8/22/2022SVB LeerinkBoost Target$50.00 ➝ $75.00Low
8/19/2022Truist FinancialBoost Target$100.00 ➝ $150.00Low
8/10/2022Cantor FitzgeraldLower Target$64.00 ➝ $54.00Low
8/10/2022Morgan StanleyBoost TargetEqual Weight$54.00 ➝ $55.00Low
7/8/2022Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $54.00N/A
6/29/2022CowenBoost TargetOutperform$120.00 ➝ $130.00Low
6/29/2022CowenBoost TargetOutperform$120.00 ➝ $130.00Low
6/29/2022Cantor FitzgeraldBoost TargetOverweight$47.00 ➝ $64.00Low
5/3/2022MizuhoLower Target$51.00 ➝ $49.00High
3/29/2022Jefferies Financial GroupBoost TargetBuy$71.00 ➝ $77.00High
3/2/2022SVB LeerinkLower TargetOutperform$65.00 ➝ $50.00Low
11/18/2021MizuhoLower TargetBuy$55.00 ➝ $51.00High
11/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2021SVB LeerinkLower TargetOutperform$75.00 ➝ $65.00High
9/15/2021HC WainwrightReiterated RatingBuy$180.00Low
8/30/2021HC WainwrightReiterated RatingBuy$225.00 ➝ $180.00Low
8/27/2021William BlairReiterated RatingBuyLow
8/23/2021MizuhoReiterated RatingBuy$55.00High
8/10/2021BTIG ResearchLower TargetBuy ➝ Buy$123.00 ➝ $55.00High
8/10/2021SVB LeerinkLower TargetPositive ➝ Outperform$115.00 ➝ $75.00High
8/10/2021Truist FinancialLower TargetBuy$200.00 ➝ $160.00High
8/10/2021MizuhoLower TargetBuy$118.00 ➝ $55.00High
8/10/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$105.00 ➝ $34.00High
7/16/2021William BlairSet TargetBuy$56.77High
6/10/2021Berenberg BankInitiated CoverageBuy$112.00High
5/26/2021Morgan StanleyBoost TargetOverweight$104.00 ➝ $105.00Medium
5/12/2021BTIG ResearchReiterated RatingBuyLow
4/27/2021HC WainwrightBoost TargetBuy$210.00 ➝ $225.00High
3/2/2021MizuhoLower TargetBuy$120.00 ➝ $118.00Low
3/2/2021Morgan StanleyBoost TargetOverweight$101.00 ➝ $104.00Low
1/8/2021Jefferies Financial GroupInitiated CoverageBuy$129.00Low
12/31/2020UBS GroupReiterated RatingPositiveN/A
12/15/2020MizuhoInitiated CoverageBuy$120.00Low
12/3/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$131.00 ➝ $161.00High
11/9/2020Morgan StanleyLower TargetOverweight$102.00 ➝ $101.00Low
10/1/2020William BlairReiterated RatingBuyLow
9/29/2020Bank of AmericaInitiated CoverageUnderperform$66.00High
9/10/2020Morgan StanleyInitiated CoverageOverweight$102.00Low
9/4/2020William BlairReiterated RatingBuyN/A
8/21/2020William BlairReiterated RatingBuyLow
8/10/2020William BlairReiterated RatingBuyMedium
8/6/2020HC WainwrightReiterated RatingBuy$210.00Low
7/14/2020HC WainwrightReiterated RatingBuy$210.00Medium
6/30/2020HC WainwrightReiterated RatingBuy$210.00High
4/28/2020GuggenheimBoost TargetIn-Line ➝ Buy$158.00 ➝ $200.00Medium
4/28/2020HC WainwrightBoost TargetBuy$200.00 ➝ $210.00Medium
4/27/2020Cantor FitzgeraldBoost TargetOverweight$125.00 ➝ $131.00Low
4/27/2020LADENBURG THALM/SH SHBoost TargetPositive ➝ Buy$165.00 ➝ $186.00Low
4/27/2020SunTrust BanksBoost TargetPositive ➝ Buy$145.00 ➝ $200.00High
4/14/2020CowenInitiated CoverageOutperform$95.00High
4/6/2020William BlairReiterated RatingBuyHigh
4/6/2020HC WainwrightReiterated RatingBuy$200.00High
3/16/2020HC WainwrightReiterated RatingBuy$200.00High
2/24/2020HC WainwrightReiterated RatingBuy$200.00Low
1/28/2020HC WainwrightReiterated RatingBuy$200.00High
1/21/2020HC WainwrightReiterated RatingBuyMedium
1/14/2020LADENBURG THALM/SH SHReiterated RatingBuy$139.00 ➝ $165.00Medium
1/2/2020SunTrust BanksBoost TargetBuy$140.00Medium
12/30/2019BTIG ResearchBoost TargetBuy$97.00Medium
12/30/2019LADENBURG THALM/SH SHBoost TargetBuy$139.00 ➝ $165.00Low
12/30/2019Cantor FitzgeraldReiterated RatingOverweight$104.00 ➝ $125.00Medium
12/24/2019HC WainwrightReiterated RatingBuy$170.00 ➝ $200.00Medium
12/17/2019SunTrust BanksBoost TargetBuy$100.00High
12/17/2019BTIG ResearchBoost TargetBuy ➝ Positive$97.00High
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$125.00Medium
12/16/2019Cantor FitzgeraldBoost TargetOverweight$55.00 ➝ $104.00High
12/4/2019GuggenheimBoost Target$65.00 ➝ $48.00High
12/4/2019SunTrust BanksReiterated RatingBuy ➝ Positive$60.00High
12/4/2019BTIG ResearchReiterated RatingBuy ➝ Positive$48.00Medium
12/3/2019Cantor FitzgeraldBoost TargetPositive ➝ Overweight$45.00 ➝ $55.00High
11/26/2019Cantor FitzgeraldReiterated RatingBuy$45.00High
10/17/2019HC WainwrightReiterated RatingBuy$30.00High
10/16/2019GuggenheimInitiated CoverageBuy$48.00High
9/18/2019William BlairInitiated CoverageOutperform$48.00Low
6/24/2019HC WainwrightSet TargetBuy$30.00Low
5/28/2019Cantor FitzgeraldReiterated RatingOverweight$25.00 ➝ $35.00Low
5/28/2019SunTrust BanksInitiated CoverageBuy ➝ BuyLow
5/23/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $30.00High
4/15/2019HC WainwrightReiterated RatingBuy ➝ Average$18.00 ➝ $23.00High
4/8/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Medium
3/28/2019BTIG ResearchBoost TargetBuy$25.00Low
3/26/2019HC WainwrightSet TargetBuy$18.00High
3/21/2019Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$16.00 ➝ $25.00High
3/15/2019HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $18.00High
3/15/2019Cantor FitzgeraldBoost TargetOverweight$13.00 ➝ $16.00High
3/5/2019HC WainwrightSet TargetBuy$15.00High
1/31/2019HC WainwrightReiterated RatingBuy$15.00Low
1/14/2019HC WainwrightReiterated RatingBuy$15.00Low
1/8/2019BTIG ResearchBoost TargetBuy$20.00High
1/7/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$34.00 ➝ $45.00High
1/7/2019HC WainwrightBoost TargetBuy$15.00High
12/10/2018Cantor FitzgeraldSet TargetBuy$16.00High
12/5/2018HC WainwrightReiterated RatingBuy$10.00High
11/15/2018Cantor FitzgeraldInitiated CoverageOverweight$16.00High
10/24/2018HC WainwrightSet TargetBuy$10.00Low
10/17/2018LADENBURG THALM/SH SHSet TargetBuy$34.00 ➝ $5.00High
10/9/2018HC WainwrightSet TargetBuy$10.00High
8/21/2018HC WainwrightReiterated RatingBuy$10.00Low
6/7/2018HC WainwrightInitiated CoverageBuy$10.00High
(Data available from 6/5/2018 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 9 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 15 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 19 very positive mentions
  • 23 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 19 very positive mentions
  • 23 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Axsome Therapeutics logo
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More

Today's Range

Now: $74.13
Low: $73.80
High: $76.50

50 Day Range

MA: $69.94
Low: $58.41
High: $80.22

52 Week Range

Now: $74.13
Low: $20.63
High: $82.85


276,203 shs

Average Volume

876,920 shs

Market Capitalization

$3.23 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?

The following Wall Street analysts have issued reports on Axsome Therapeutics in the last year: Bank of America Co., BTIG Research, Cantor Fitzgerald, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Loop Capital, Mizuho, Morgan Stanley, Piper Sandler,, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for AXSM.

What is the current price target for Axsome Therapeutics?

14 Wall Street analysts have set twelve-month price targets for Axsome Therapeutics in the last year. Their average twelve-month price target is $105.57, suggesting a possible upside of 42.4%. HC Wainwright has the highest price target set, predicting AXSM will reach $200.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $52.00 for Axsome Therapeutics in the next year.
View the latest price targets for AXSM.

What is the current consensus analyst rating for Axsome Therapeutics?

Axsome Therapeutics currently has 1 sell rating, 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXSM will outperform the market and that investors should add to their positions of Axsome Therapeutics.
View the latest ratings for AXSM.

What other companies compete with Axsome Therapeutics?

How do I contact Axsome Therapeutics' investor relations team?

Axsome Therapeutics' physical mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company's listed phone number is (212) 332-3241. The official website for Axsome Therapeutics is Learn More about contacing Axsome Therapeutics investor relations.